Nabi Biopharmaceuticals’ Nabi-HB™ Intravenous Received Positive Opinion from USFDA Blood Products Advisory Committee (BPAC)
The Blood Products Advisory Committee (BPAC) of the USFDA gave a positive opinion of Nabi Biopharmaceuticals’ Biologic License Application (BLA) for Nabi-HB™ Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] in last week’s meeting.
Nabi-HB™ Intravenous’ BLA has been submitted by Nabi Biopharmaceuticals in November 2002 and has received Orphan Drug status in the United States.
The USFDA Blood Products Advisory Committee voted to recommend approval of the use of Nabi- HB™ Intravenous for the prevention of recurrence of hepatitis B after liver transplant.
Read more at Nabi Biopharmaceuticals.
Comment Preview